Atopic Dermatitis News and Research

RSS
Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.
NIH-funded study identifies genetic markers associated with eosinophilic esophagitis

NIH-funded study identifies genetic markers associated with eosinophilic esophagitis

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Study gives parents, doctors new options to treat children with eczema

Study gives parents, doctors new options to treat children with eczema

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Celsus’ expert highlights serious side effects of topical corticosteroids

Celsus’ expert highlights serious side effects of topical corticosteroids

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus’ shares to begin trading on NYSE MKT on  May 16, 2014

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Zoetis’ revenue increases $1.1B to 1% in first quarter 2014

Zoetis’ revenue increases $1.1B to 1% in first quarter 2014

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Zoetis reports revenue of $1.25 billion for Q4 2013

Zoetis reports revenue of $1.25 billion for Q4 2013

Mother's illness, allergen exposure during pregency may predict child's risk of asthma and allergy

Mother's illness, allergen exposure during pregency may predict child's risk of asthma and allergy

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Loyola professor receives prestigious Presidential Early Career Award for Scientists and Engineers

Loyola professor receives prestigious Presidential Early Career Award for Scientists and Engineers

Discovery opens new therapeutic avenue for chronic skin condition affecting millions

Discovery opens new therapeutic avenue for chronic skin condition affecting millions

Asthma link to mood disorders strengthened

Asthma link to mood disorders strengthened

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

FDA accepts Regeneron's EYLEA Injection sBLA for standard review